arrow
S

Stanford L. Peng

Vertex Pharmaceuticals
H指数:43
被引数:9,186

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Povetacicept Displays Enhanced Serum Exposure and Improved Tissue Distribution Relative to Wild-Type TACI-Fc Molecules

Povetacicept相对于野生型TACI-Fc分子显示出增强的血清暴露和改善的组织分布

2026-11-060
OAAI
Case report of fatal immune-mediated myocarditis following treatment with davoceticept (ALPN-202), a PD-L1-dependent CD28 costimulator and dual PD-L1/CTLA-4 checkpoint inhibitor, in combination with pembrolizumab
2024-08-131
OAAI
Povetacicept, an Enhanced Dual APRIL/BAFF Antagonist That Modulates B Lymphocytes and Pathogenic Autoantibodies for the Treatment of Lupus and Other B Cell-Related Autoimmune Diseases

Povetacicept,一种增强的APRIL/BAFF双重拮抗剂,可调节B淋巴细胞和致病性自身抗体,用于治疗狼疮和其他b细胞相关的自身免疫性疾病

2023-04-1920
OA
The engineered CD80 variant fusion therapeutic davoceticept combines checkpoint antagonism with conditional CD28 costimulation for anti-tumor immunity
2022-04-0418
OAAI
ICOSL+ plasmacytoid dendritic cells as inducer of graft-versus-host disease, responsive to a dual ICOS/CD28 antagonist
2020-10-0719
OAAI
The relapsing polychondritis damage index (RPDAM): Development of a disease-specific damage score for relapsing polychondritis
2019-05-0112
OAAI
The Relapsing Polychondritis Disease Activity Index: Development of a disease activity score for relapsing polychondritis
2012-12-0161
PRE